It reported that 70–90% of ALL patients show durable responses to CD19 CAR-T therapy in the initial phase; however, it was followed by the downregulation or loss of CD19 antigen expression in 30–70% of the recurrent proportions (63). Here, CD19 is linked to acute lymphoblastic leukemia.